Evidence map›Paper›PMID 36075963›Full record

ArticleMolecular psychiatry2022

The orphan receptor GPR88 controls impulsivity and is a risk factor for Attention-Deficit/Hyperactivity Disorder.

Sami Ben Hamida, Sarojini M Sengupta, Ellie Clarke, Michael McNicholas, Eleonora Moroncini, Emmanuel Darcq, Marina Ter-Stepanian, Marie-Ève Fortier, Natalie Grizenko, Ridha Joober and 1 more

Open access · greenAbstract read
In one paragraph

Article in Molecular psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Sami Ben HamidaDouglas Mental Health University Institute, Montreal, QC, Canada.ORCID http://orcid.org/0000-0001-9636-9432
Sarojini M SenguptaDouglas Mental Health University Institute, Montreal, QC, Canada.
Ellie ClarkeDouglas Mental Health University Institute, Montreal, QC, Canada.
Michael McNicholasDouglas Mental Health University Institute, Montreal, QC, Canada.
Eleonora MoronciniDouglas Mental Health University Institute, Montreal, QC, Canada.
Emmanuel DarcqDouglas Mental Health University Institute, Montreal, QC, Canada.ORCID http://orcid.org/0000-0002-8377-8015
Marina Ter-StepanianDepartment of Educational and Counselling Psychology, McGill University Montreal, Montreal, QC, Canada.
Marie-Ève FortierDouglas Mental Health University Institute, Montreal, QC, Canada.
Natalie GrizenkoDouglas Mental Health University Institute, Montreal, QC, Canada.
Ridha JooberDouglas Mental Health University Institute, Montreal, QC, Canada.
Brigitte L KiefferDouglas Mental Health University Institute, Montreal, QC, Canada. brigitte.kieffer@unistra.fr.ORCID http://orcid.org/0000-0002-8809-8334
Douglas Mental Health University Institute · CAInserm · FRUniversité de Sherbrooke · CA

Funding

Nr4a1 and GPR88 as novel gene targets for alcoholism: mouse genetic approachesU01AA016658 · NIAAA · UNIVERSITE DE STRASBOURG · PI LAURA ADELA HARSAN · 2006 to 2026
$3.8M
NIAAA NIH HHS U01 AA016658U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (NIAAA) 16658
6 · The paper itself

Abstract

The neural orphan G protein coupled receptor GPR88 is predominant in the striatum and cortex of both rodents and humans, and considered a potential target for brain disorders. Previous studies have shown multiple behavioral phenotypes in Gpr88 knockout mice, and human genetic studies have reported association with psychosis. Here we tested the possibility that GPR88 contributes to Attention Deficit Hyperactivity Disorder (ADHD). In the mouse, we tested Gpr88 knockout mice in three behavioral paradigms, best translatable between rodents and humans, and found higher motor impulsivity and reduced attention together with the reported hyperactivity. Atomoxetine, a typical ADHD drug, reduced impulsivity in mutant mice. Conditional Gpr88 knockout mice in either D1R-type or D2R-type medium spiny neurons revealed distinct implications of the two receptor populations in waiting and stopping impulsivity. Thus, animal data demonstrate that deficient GPR88 activity causally promotes ADHD-like behaviors, and identify circuit mechanisms underlying GPR88-regulated impulsivity. In humans, we performed a family-based genetic study including 567 nuclear families with DSM-IV diagnosis of ADHD. There was a minor association for SNP rs2036212 with diagnosis, treatment response and cognition. A stronger association was found for SNP rs2809817 upon patient stratification, suggesting that the T allele is a risk factor when prenatal stress is involved. Human data therefore identify GPR88 variants associated with the disease, and highlight a potential role of life trajectories to modulate GPR88 function. Overall, animal and human data concur to suggest that GPR88 signaling should be considered a key factor for diagnostic and treatment of ADHD.

Indexed as

Attention Deficit Disorder with HyperactivityAnimalsCarrier ProteinsCorpus StriatumHumansImpulsive BehaviorMiceMice, KnockoutReceptors, G-Protein-CoupledRisk FactorsCarrier ProteinsGpr88 protein, mouseReceptors, G-Protein-Coupled

Identifiers

PMID36075963
PMCPMC9936886
OpenAlexW4295086707

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.